In addition, we demonstrated that ME1 potentially refines the ELN risk categorization for HSCT-treated patients, while also being correlated with a tumor-supportive microenvironment, non-GMP-like AML blasts subtype, and specific AML drug sensitivity. This evidence concerns the gene ME1 and acute myeloid leukemia.